Peptides / Growth hormone axis

Synthetic analog · 6 amino acids · 873 Da

GHRP-6

Not approvedBanned in sport

GHRP-6 is a synthetic six-amino-acid peptide that acts on the ghrelin receptor to release growth hormone. It is not approved and is banned in sport, and studies in people measured growth hormone and stress hormone levels. PepBank shows 187 results on GHRP-6 from 49 studies in people, and 755 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as CIGB-500, SK&F-110679, SKF-110679, U-75799E, Growth hormone releasing hexapeptide, Growth hormone-releasing peptide 6 and 2 more

6 amino acids, from first to lastHWAWFK

Evidence level: Mostly animal studies755 of 942 results come from studies in animals and lab cells. 49 studies in people.

Results in people

187

20% of 942 results

Results in animals

483

51% of 942 results

Results in lab cells

272

29% of 942 results

From computer models

0% of 942 results

Overview

GHRP-6 at a glance

What it is	Synthetic analog, 6 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2.2.4)
Studies	359 studies with results. 217 of them gave GHRP-6, with 942 results. 187 in people483 in animals272 in lab cells
Best study in people	Randomized controlled trial with 21 people (1997)
Clinical trials	None registered
Community use	Growth hormone release; Appetite during bulking; Recovery before sleep

The science

What is GHRP-6?

Synthetic hexapeptide that activates the ghrelin receptor and releases growth hormone. It is not an approved medicine.

Amino acids in one chain

GHRP-6 structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 6 amino acidsFrom the first amino acid to the last

H1WAWF5+K

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

GHRP-6 is a synthetic analog of 6 amino acids, with no ring, 3 changed amino acids.

Formula

C₄₆H₅₆N₁₂O₆

Molecular weight

873 g/mol

CAS number

87616-84-0

Target

Growth hormone secretagogue receptor type 1a (ghrelin receptor) (gene GHSR): agonistEvidence: primary literature

Development

Originally SmithKline Beecham (SK&F-110679); now the Center for Genetic Engineering and Biotechnology, Cuba (CIGB), for the product CIGB-500 and the EGF plus GHRP-6 combination. Highest phase: phase 3.

Identifiers

PubChem 9919153, ChEMBL CHEMBL105462, UNII 4H7N4I6X6A, IUPHAR 1093

Full sequence, SMILES and InChIKey

Three-letter sequence
H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

InChIKey
WZHKXNSOCOQYQX-FUAFALNISA-N

SMILES
C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC6=CN=CN6)N

See charge, composition and 3D structure on the Scientific page

The evidence

What GHRP-6 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies755 of 942 results come from studies in animals and lab cells. 49 studies in people.

Growth hormone and growth

381 results · 117 in people · 160 animal · 104 lab

GHRP‑6 raised growth hormone to a similar level in people with an underactive thyroid and in controls, with a trend to smaller responses in patients. Clinical endocrinology, 1997

Top results

GHRP‑6 raised growth hormone to a similar level in people with an underactive thyroid and in controls, with a trend to smaller responses in patients. (Clinical endocrinology, 1997)
In rats, GHRP‑6 increased hypothalamic insulin-like growth factor I production compared with saline. (Endocrinology, 2014)
In shrimp, GHRP‑6 increased body size. (Aquaculture research., 2017)

Hormones

58 results · 37 in people · 13 animal · 8 lab

In healthy men, GHRP‑6 raised the stress hormone ACTH more than placebo. Neuroendocrinology, 1995

Top results

In healthy men, GHRP‑6 raised the stress hormone ACTH more than placebo. (Neuroendocrinology, 1995)
In healthy men, the highest GHRP dose raised prolactin about 2-fold above its starting level. (The Journal of clinical endocrinology and metabolism, 1990)
In healthy young men, GHRP infusion lowered baseline thyroid-stimulating hormone versus saline infusion. (The Journal of clinical endocrinology and metabolism, 1993)

Sleep

11 results · 6 in people · 5 animal

In healthy men, GHRP‑6 increased the time in stage 2 sleep compared with placebo. Neuroendocrinology, 1995

Top results

In healthy men, GHRP‑6 increased the time in stage 2 sleep compared with placebo. (Neuroendocrinology, 1995)
In mice with free access to food, GHRP‑6 did not change the timing of the body clock. (The Journal of neuroscience, 2007)
In mice, peripheral GHRP‑6 reduced light-induced delays in circadian timing by 45%. (The European journal of neuroscience, 2008)

Sex hormones and fertility

15 results · 4 in people · 11 lab

In healthy men, luteinising hormone did not change in the first hour after GHRP. The Journal of clinical endocrinology and metabolism, 1990

Top results

In healthy men, luteinising hormone did not change in the first hour after GHRP. (The Journal of clinical endocrinology and metabolism, 1990)
In lab tests on chicken ovarian tissue, GHRP6 increased progesterone release. (Domestic animal endocrinology, 2008)
In healthy men, injected GHRP slightly raised blood prolactin. (Endocrinologia japonica, 1991)

Blood sugar

18 results · 3 in people · 13 animal · 2 lab

In controls and in people with an overactive thyroid, GHRP‑6 did not raise blood glucose. Pituitary, 2007

Top results

In controls and in people with an overactive thyroid, GHRP‑6 did not raise blood glucose. (Pituitary, 2007)
In older calves, GHRP‑6 briefly raised insulin in the blood. (The Journal of endocrinology, 2004)
In healthy men, GHRP did not change blood insulin. (Endocrinologia japonica, 1991)

Weight and appetite

49 results · 49 animal

In rats, GHRP‑6 injected into the brain increased food intake. Endocrinology, 2002

Top results

In rats, GHRP‑6 injected into the brain increased food intake. (Endocrinology, 2002)
In female rats, 12 weeks of GHRP‑6 raised body weight compared with vehicle. (The Journal of endocrinology, 2000)
In rats with adrenal glands, GHRP‑6 increased groin fat pad weight compared with saline. (European journal of endocrinology, 2004)

All 359 GHRP-6 studies by area Open the Scientific page

Key GHRP-6 studies

Studies in people come first, then studies in animals and in the lab.

People
Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism
Pimentel-Filho et al. 1997 · Clinical endocrinology · 21 people · cited by 5
3 results
People
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood
Micic et al. 1995 · Clinical endocrinology · 18 people · cited by 18
4 results
People
Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release
Nooitgedagt et al. 1997 · Clinical endocrinology · 11 people · cited by 5
3 results
People
Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism
Borges et al. 1997 · Clinical endocrinology · 9 people · cited by 11
2 results
People
Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man
Pinto et al. 1999 · Clinical endocrinology · 8 people · cited by 6
2 results

All 359 GHRP-6 studies

GHRP-6 clinical trials

ClinicalTrials.gov lists no trial of GHRP-6. A trial under another name may exist.

Status and safety

Is GHRP-6 approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.4.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026). Banned in sport (WADA S2.2.4).

Laws and labels change, so check the regulator for the current status.

GHRP-6 side effects and safety

PepBank has 32 safety results from studies of GHRP-6. 11 of them come from studies in people.

Safety results from studies (32)

No side effects were observed during GHRP6 testing. (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2009)
In patients with suspected adrenal problems, no side effects were detected with the GHRP6 test. (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010)
In adults tested for pituitary or adrenal disease, the only side effects seen with GHRP‑6 were flushing symptoms. (European journal of endocrinology, 2002)
In healthy men, GHRP caused no adverse clinical effects or laboratory abnormalities in this short study. (The Journal of clinical endocrinology and metabolism, 1990)
The study reported that all men tolerated GHRP well. (The Journal of clinical endocrinology and metabolism, 1989)
In healthy men, GHRP did not change blood TSH. (Endocrinologia japonica, 1991)
In healthy men, GHRP did not change blood LH. (Endocrinologia japonica, 1991)
In healthy men, GHRP did not change blood FSH. (Endocrinologia japonica, 1991)
In healthy men, GHRP did not change blood insulin. (Endocrinologia japonica, 1991)
In healthy men, GHRP did not change blood sugar. (Endocrinologia japonica, 1991)
In healthy men, seven nasal doses of GHRP given every 8 hours were well tolerated. (Endocrinologia japonica, 1991)
In dogs, irregular heartbeats did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion. (The Journal of pharmacology and experimental therapeutics, 2003)
In swine, GHRP‑6 raised blood levels of the stress hormone ACTH. (European journal of endocrinology, 1998)
In rats, researchers observed no gliosis after any treatment, including GHRP‑6. (Endocrinology, 2014)
In pigs with coronary occlusion, GHRP6 did not change deaths during surgery compared with saline. (Clinical science, 2007)
In rats receiving doxorubicin, GHRP‑6 reduced deaths compared with doxorubicin alone. (Frontiers in pharmacology, 2024)
In rabbits, GHRP6 did not produce the unwanted reactions that triamcinolone acetonide produced. (International wound journal, 2018)
In mice, intranasal GHRP‑6 increased food intake without adverse effects. (Endocrinology, 2025)
In fish, dietary GHRP‑6 did not produce intestinal tissue alterations. (Biology, 2025)
In dogs, CIGB-500 produced temporary hypersalivation in some animals at the higher doses, considered non-adverse. (Regulatory toxicology and pharmacology, 2025)
In dogs, none died with GHRP‑6 during coronary occlusion, compared with 55% survival with vehicle. (The Journal of pharmacology and experimental therapeutics, 2003)
In dogs, none died with GHRP‑6 during coronary occlusion, compared with 57% survival with GH. (The Journal of pharmacology and experimental therapeutics, 2003)
In swine, GHRP‑6 raised blood levels of the stress hormone cortisol. (European journal of endocrinology, 1998)
In fish, dietary GHRP‑6 did not produce spleen tissue alterations. (Biology, 2025)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 21	Pimentel-Filho 1997
90 micrograms	Human	human	intravenous bolus	Not reported	Randomized trial in people · n = 18	Micic 1995
100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 11	Nooitgedagt 1997
1 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 9	Borges 1997
1 microg/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 8	Pinto 1999
4 x 50 micrograms	Human	human	intravenous	Not reported	Randomized trial in people	Frieboes 1995
1 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 49	Alaioubi 2010
1 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 69	Alaioubi 2009
1 microgram/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 37	Peñalva 1993
1 microg/kg	Human	human	iv	Not reported	Trial in people without random groups · n = 31	Grugni 2001
90 microg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 29	Micić 1999
90 micrograms	Human	human	intravenous	Not reported	Trial in people without random groups · n = 23	Popovic 1995
1 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 20	Petersenn 2002
1 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 20	Correa-Silva 2006
0.1 microgram/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 18	Bowers 1990
0.3 microgram/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 18	Bowers 1990
1.0 microgram/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 18	Bowers 1990
0.1, 0.3 and 1.0 microgram/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 18	Bowers 1990
1 microgram/kg	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 18	Bowers 1990
1 µg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 18	Nascif 2007
0.05 to 2.5 micrograms/kg	Human	human	intravenous infusion	30 min	Trial in people without random groups · n = 17	Ilson 1989
300 micrograms/kg	Human	human	oral	Not reported	Trial in people without random groups · n = 16	Ghigo 1994
100 micrograms	Human	human	intravenous	Not reported	Trial in people without random groups · n = 15	Leal-Cerro 1994
1 ug/kg	Human	human	iv	single dose	Trial in people without random groups · n = 13	Martins 2003
90 micrograms	Human	human	intravenous	Not reported	Trial in people without random groups · n = 12	Popovic 1994
90 microg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 12	Catalina 1998
2 microg/kg	Human	human	iv	single bolus	Trial in people without random groups · n = 10	Oliveira 2003
300 micrograms/kg	Human	human	oral	Not reported	Trial in people without random groups · n = 9	Bowers 1992
1 microgram/kg loading bolus, then 1 microgram/kg.h	Human	human	intravenous	34 h	Trial in people without random groups · n = 9	Jaffe 1993
100, 200 and 400 μg/kg	Human	human	intravenous bolus	single dose	Trial in people without random groups · n = 9	Cabrales 2013
1 microgram/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 7	Pombo 1995
300 micrograms/kg	Human	human	oral	Not reported	Trial in people without random groups · n = 7	Bellone 1995
300 micrograms/kg	Human	human	oral	Not reported	Trial in people without random groups · n = 7	Ghigo 1994
1 microgram/kg body weight	Human	human	intravenous	Not reported	Trial in people without random groups · n = 6	Hayashi 1991
30 micrograms/kg body weight	Human	human	intranasal	Not reported	Trial in people without random groups · n = 6	Hayashi 1991
15 micrograms/kg body weight	Human	human	intranasal	Not reported	Trial in people without random groups · n = 6	Hayashi 1991
5 micrograms/kg body weight	Human	human	intranasal	Not reported	Trial in people without random groups · n = 6	Hayashi 1991
1 microg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 6	Micic 2002
100 micrograms/kg	Human	human	oral	Not reported	Trial in people without random groups · n = 5	Bowers 1992
1 microgram/kg body weight	Human	human	intravenous	Not reported	Trial in people without random groups · n = 5	Robinson 1992

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

A community wiki reports GHRP-6 use for growth hormone release, appetite during bulking and recovery before sleep. It describes single-product and GHRH combination regimens.

Reported routines and cautions

What people use it for

Growth hormone releaseS1
Appetite during bulkingS1
Recovery before sleepS1

Reported regimens

Regimens that community sources report for GHRP-6. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
General growth hormone release	subcutaneous injection	100 to 200 mcg per dose	2-3 times daily	8-12 weeks	Single source. The source carries seller advertisements or affiliate links.	S1
Combination with Mod GRF 1-29	subcutaneous injection	100 mcg per dose	2-3 times daily	8-16 weeks	Single source. The source carries seller advertisements or affiliate links.	S1
Appetite and bulking	subcutaneous injection	100 to 200 mcg per dose	2-3 times daily, 30 minutes before meals	4-8 weeks	Single source. The source carries seller advertisements or affiliate links.	S1
Before sleep	subcutaneous injection	100 to 200 mcg per dose	Once daily before bed	8-12 weeks	Single source. The source carries seller advertisements or affiliate links.	S1

Reported side effects

Marked hungerS1

Cautions

The source identifies cortisol and prolactin elevation as concerns. These reports do not establish safe repeated dosing.S1

Community sources

S1GHRP-6 community protocolswww.peptideprotocolwiki.comcarries seller links, not linked

Gaps

One affiliate wiki supports all regimens. It compiles reports rather than verified treatment records. The page labels its content unverified. It names a recovery protocol but does not report recovery benefits or specify exercise recovery. No independent underlying community reports were checked. The cited page supplies no official-label regimen. Approval status remains outside this source check.

Questions and more

Ask a question about GHRP-6

The answer links to every study it uses.

What does the evidence say about GHRP-6?Is GHRP-6 tested in people?Compare with Hexarelin Compare with HGH (somatotropin)

Sources

Database: PepBank data for GHRP-6 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about GHRP-6

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

GHRP-6

Not approvedBanned in sport

Also known as CIGB-500, SK&F-110679, SKF-110679, U-75799E, Growth hormone releasing hexapeptide, Growth hormone-releasing peptide 6 and 2 more

What it is

Synthetic analog, 6 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2.2.4)

Studies

359 studies with results. 217 of them gave GHRP-6, with 942 results.
187 in people483 in animals272 in lab cells

Best study in people

Randomized controlled trial with 21 people (1997)

Clinical trials

None registered

Community use

Growth hormone release; Appetite during bulking; Recovery before sleep

Dose as reported

Class

Species

Route

Duration

Design

Source

1 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 21

Pimentel-Filho 1997

90 micrograms

Human

human

intravenous bolus

Not reported

Randomized trial in people · n = 18

Micic 1995

100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 11

Nooitgedagt 1997

1 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 9

Borges 1997

1 microg/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 8

Pinto 1999

4 x 50 micrograms

Human

human

intravenous

Not reported

Randomized trial in people

Frieboes 1995

1 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 49

Alaioubi 2010

1 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 69

Alaioubi 2009

1 microgram/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 37

Peñalva 1993

1 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 31

Grugni 2001

90 microg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 29

Micić 1999

90 micrograms

Human

human

intravenous

Not reported

Trial in people without random groups · n = 23

Popovic 1995

1 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 20

Petersenn 2002

1 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 20

Correa-Silva 2006

0.1 microgram/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 18

Bowers 1990

0.3 microgram/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 18

Bowers 1990

1.0 microgram/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 18

Bowers 1990

0.1, 0.3 and 1.0 microgram/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 18

Bowers 1990

1 microgram/kg

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 18

Bowers 1990

1 µg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 18

Nascif 2007

0.05 to 2.5 micrograms/kg

Human

human

intravenous infusion

30 min

Trial in people without random groups · n = 17

Ilson 1989

300 micrograms/kg

Human

human

oral

Not reported

Trial in people without random groups · n = 16

Ghigo 1994

100 micrograms

Human

human

intravenous

Not reported

Trial in people without random groups · n = 15

Leal-Cerro 1994

1 ug/kg

Human

human

single dose

Trial in people without random groups · n = 13

Martins 2003

90 micrograms

Human

human

intravenous

Not reported

Trial in people without random groups · n = 12

Popovic 1994

90 microg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 12

Catalina 1998

2 microg/kg

Human

human

single bolus

Trial in people without random groups · n = 10

Oliveira 2003

300 micrograms/kg

Human

human

oral

Not reported

Trial in people without random groups · n = 9

Bowers 1992

1 microgram/kg loading bolus, then 1 microgram/kg.h

Human

human

intravenous

34 h

Trial in people without random groups · n = 9

Jaffe 1993

100, 200 and 400 μg/kg

Human

human

intravenous bolus

single dose

Trial in people without random groups · n = 9

Cabrales 2013

1 microgram/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 7

Pombo 1995

300 micrograms/kg

Human

human

oral

Not reported

Trial in people without random groups · n = 7

Bellone 1995

300 micrograms/kg

Human

human

oral

Not reported

Trial in people without random groups · n = 7

Ghigo 1994

1 microgram/kg body weight

Human

human

intravenous

Not reported

Trial in people without random groups · n = 6

Hayashi 1991

30 micrograms/kg body weight

Human

human

intranasal

Not reported

Trial in people without random groups · n = 6

Hayashi 1991

15 micrograms/kg body weight

Human

human

intranasal

Not reported

Trial in people without random groups · n = 6

Hayashi 1991

5 micrograms/kg body weight

Human

human

intranasal

Not reported

Trial in people without random groups · n = 6

Hayashi 1991

1 microg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 6

Micic 2002

100 micrograms/kg

Human

human

oral

Not reported

Trial in people without random groups · n = 5

Bowers 1992

1 microgram/kg body weight

Human

human

intravenous

Not reported

Trial in people without random groups · n = 5

Robinson 1992

Context

Route

Amount

How often

How long

Agreement

Sources

General growth hormone release

subcutaneous injection

100 to 200 mcg per dose

2-3 times daily

8-12 weeks

Single source. The source carries seller advertisements or affiliate links.

Combination with Mod GRF 1-29

subcutaneous injection

100 mcg per dose

2-3 times daily

8-16 weeks

Single source. The source carries seller advertisements or affiliate links.

Appetite and bulking

subcutaneous injection

100 to 200 mcg per dose

2-3 times daily, 30 minutes before meals

4-8 weeks

Single source. The source carries seller advertisements or affiliate links.

Before sleep

subcutaneous injection

100 to 200 mcg per dose

Once daily before bed

8-12 weeks

Single source. The source carries seller advertisements or affiliate links.

GHRP-6

GHRP-6 at a glance

What is GHRP-6?

GHRP-6 structure and chemistry

What GHRP-6 studies show

Growth hormone and growth

Hormones

Sleep

Sex hormones and fertility

Blood sugar

Weight and appetite

Key GHRP-6 studies

GHRP-6 clinical trials

Is GHRP-6 approved?

GHRP-6 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Cautions

Community sources

Ask a question about GHRP-6

Related peptides

Sources

GHRP-6

GHRP-6 at a glance

What is GHRP-6?

GHRP-6 structure and chemistry

What GHRP-6 studies show

Growth hormone and growth

Hormones

Sleep

Sex hormones and fertility

Blood sugar

Weight and appetite

Key GHRP-6 studies

GHRP-6 clinical trials

Is GHRP-6 approved?

GHRP-6 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Cautions

Community sources

Ask a question about GHRP-6

Related peptides

Sources